Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting
Luxa Biotechnology LLC (Luxa) today announced the company will present Phase 1/2a clinical and preclinical data on the company’s adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD) at the 2025 ARVO Annual Meeting taking place May 4-8, 2025 in Salt Lake City, Utah.
Clinical outcomes demonstrating vision improvement from the low-dose cohort of the ongoing first-in-human Phase 1/2a clinical trial (NCT04627428) will be shared.
Details of the two podium presentations are as follows:
Title: Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Implantation in Patients with Dry AMD: Early Low Dose Clinical Outcomes
Presenter: Dr. Jeffrey Stern
Session: Clinical Advances in Cell and Gene Therapy
Number: Paper Session, Presentation #2701
Date/Time: Tuesday, May 6, 2025 | 9:00–9:15 AM MT
Location: Ballroom B
Title: Preclinical Safety and Efficacy of an Adult Progenitor Cell Product, RPESC-RPE-4W, as Therapy for Dry AMD
Presenter: Dr. Brigitte Arduini
Session: Stem Cell and Gene Therapy
Number: Paper Session, Presentation #876
Date/Time: Sunday, May 4, 2025 | 3:15–3:30 PM MT
Location: Room 255E
The article
https://www.koreabiomed.com/news/articleView.html?idxno=27413
